Medical University Innsbruck, Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Anichstr. 35, 6020 Innsbruck, Austria.
Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan; Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychosis Studies, London, UK.
Eur Psychiatry. 2017 Oct;46:42-47. doi: 10.1016/j.eurpsy.2017.08.005. Epub 2017 Sep 1.
Health-related quality of life (HRQOL) is significantly affected in individuals with schizophrenia or bipolar I disorder (BD-I). The current study investigated whether symptomatic remission and resilience might differently impact HRQOL in these patients.
Fifty-two patients with schizophrenia and 60 patients suffering from BD-I from outpatient mental health services as well as 77 healthy control subjects from the general community were included into a cross-sectional study. HRQOL and resilience were assessed using the WHOQOL-BREF and the Resilience Scale. In patients, psychopathology was quantified by the Positive and Negative Syndrome Scale or the Montgomery Asberg Depression Rating Scale and the Young Mania Rating Scale, respectively.
Notably, both patient groups showed lower HRQOL and resilience compared to control subjects, non-remitted patients indicated lower HRQOL than remitted ones. The effect of remission on HRQOL was significantly larger in patients with BD-I than in those with schizophrenia but did not explain the difference in HRQOL between groups. Resilience predicted HRQOL in all three groups. When accounting for the effect of resilience among remitted patients, only the difference in HRQOL between schizophrenia patients and control subjects was significant.
These findings demonstrate the impact of symptomatic remission and resilience on HRQOL of both patients suffering from schizophrenia and BD-I and indicate that these factors are especially relevant for HRQOL of patients with BD-I.
精神分裂症或双相情感障碍 I 型（BD-I）患者的健康相关生活质量（HRQOL）受到显著影响。本研究旨在探讨症状缓解和韧性是否会对这些患者的 HRQOL 产生不同的影响。
将 52 名精神分裂症患者和 60 名门诊心理健康服务中患有 BD-I 的患者以及 77 名来自普通社区的健康对照纳入横断面研究。使用 WHOQOL-BREF 和韧性量表评估 HRQOL 和韧性。在患者中，通过阳性和阴性综合征量表或蒙哥马利抑郁评定量表和杨氏躁狂评定量表分别量化精神病理学。
值得注意的是，与对照组相比，两组患者的 HRQOL 和韧性均较低，未缓解患者的 HRQOL 低于缓解患者。BD-I 患者的缓解对 HRQOL 的影响明显大于精神分裂症患者，但不能解释两组之间 HRQOL 的差异。韧性在所有三组中均预测 HRQOL。在考虑缓解患者的韧性效应后，仅精神分裂症患者和对照组之间的 HRQOL 差异具有统计学意义。
这些发现表明症状缓解和韧性对精神分裂症和 BD-I 患者的 HRQOL 均有影响，并表明这些因素对 BD-I 患者的 HRQOL 尤为重要。
